Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Nyloxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. See: www.nyloxin.com Nutra Pharma also offers Pet Pain-Away: a product aimed at treating moderate to severe chronic pain in companion animals. Pet Pain-Away is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs and cats. In addition to the Company's OTC products, Nutra pharma is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. In 2015, the company was granted Orphan Designation for it's drug, RPI-78M for the treatment of pediatric Multiple Sclerosis. Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates and joint venture partners.